Table 1.
The clinical efficacy of MSCs for treatment of ITP patients
| No | Age/gender (years) | Duration (months) | Previous treatment | MSC type | Dose (106/kg) | Times | Platelet counts 109/L | Time to response (days) | Overall response | Response duration (months) | Refs | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | |||||||||||
| 1 | 21/M | 43 | P,V,A,C,Ig,S,Cy,PBSCT | AMSC | 2 | 1 | 9 | 51 | 11 | Yes | 55 | [43] |
| 2 | 34/F | 71 | P,V,A,C,Ig,S,Cy | AMSC | 2 | 1 | 12 | 92 | 11 | Yes | 19 | |
| 3 | 45/M | 62 | P,Ig,A,D,De,S | AMSC | 2 | 1 | 5 | 103 | 12 | Yes | 13 | |
| 4 | 32/F | 53 | P,D,V,A,Ig,S | AMSC | 2 | 2 | 11 | 91 | 11 | Yes | 8.5 | |
| 5 | 29/M | 37 | P,D,V,A,S,Cy | AMSC | 2 | 1 | 15 | 104 | 17 | Yes | 12 | |
| 6 | 22/F | 74 | P,De,V,A,S | AMSC | 2 | 2 | 3 | 45 | 12 | Yes | 10 | |
| 7 | 38/M | 14 | P,A,S,V | AMSC | 2 | 2 | 10 | 99 | 16 | Yes | 8.7 | |
| 8 | 26/M | 43 | P,V,Cy,Ig,S | UCMSC | 1 | 1 | 8 | 56 | 7 | Yes | 24 | [44] |
| 9 | 49/F | 71 | P,V,Cy,Ig | UCMSC | 1 | 2 | 9 | 94 | 13 | Yes | 18 | |
| 10 | 54/F | 62 | P,Ig,Cy,De,S | UCMSC | 1 | 2 | 5 | 103 | 16 | Yes | 13 | |
| 11 | 50/F | 120 | P,Ig,V | UCMSC | 1 | 2 | 3 | 56 | 14 | Yes | 13 | |
| 12 | 64/M | 54 | P,D,Ig,S,De,C, | UCMSC | 0.4 | 1 | 1 | 33 | 7 | Yes | 3 | [36] |
| 13 | 66/F | 49 | P,D,Ig,S,R, | UCMSC | 0.4 | 1 | 12 | 59 | 14 | Yes | 9 | |
F, female; M, male; P, prednisone; V, vincristine; A, azathioprine; C, cyclophosphamide; Ig, intravenous immunoglobulins; S, splenectomy; Cy, cyclosporin A; PBSCT, peripheral blood stem cells transplantation; D, danazol; De, dexamethasone; R, rituximab; AMSC, adipose tissue-derived mesenchymal stem cell; UCMSC, umbilical cord mesenchymal stem cells; response: platelet count ≥ 30,000/µL and at least doubling baseline